2009 Annual Report
1a.Objectives (from AD-416)
Develop an integrated risk model for toxoplasma in the U.S. pork industry.
1b.Approach (from AD-416)
Will test various drug or vaccine candidates in mice experimentally-infected with Toxoplasma strains of different genotypes.
This is a multi-institutional five year agreement funded through National Institutes of Health. The main objective is to develop a protective vaccine for Toxoplasma. The infectivity and pathogenicity of three genotypes of Toxoplasma gondii (Types III, II, and I) oocysts were compared in 2 strains of mice, Swiss Webster outbred mice and BALB/c inbred mice; no differences were found with respect to strain of the mouse. Therefore, either strain of mice maybe used in future studies. Project plans, goals, and accomplishments were discussed via conference calls and e-mail; technical advice was provided to the Cooperator in writing and by teleconference.